Literature DB >> 33420376

Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.

Duojiao Chen1, Taylor M Parker2, Poornima Bhat-Nakshatri2, Xiaona Chu1, Yunlong Liu1, Yue Wang3, Harikrishna Nakshatri4,5,6.   

Abstract

Chromatin accessibility is central to basal and inducible gene expression. Through ATAC-seq experiments in estrogen receptor-positive (ER+) breast cancer cell line MCF-7 and integration with multi-omics data, we found estradiol (E2) induced chromatin accessibility changes in a small number of breast cancer-relevant E2-regulated genes. As expected, open chromatin regions associated with E2-inducible gene expression showed enrichment of estrogen response element (ERE) and those associated with E2-repressible gene expression were enriched for ERE, PBX1, and PBX3. While a significant number of open chromatin regions showed pioneer factor FOXA1 occupancy in the absence of E2, E2-treatment further enhanced FOXA1 occupancy suggesting that ER-E2 enhances chromatin occupancy of FOXA1 to a subset of E2-regulated genes. Surprisingly, promoters of 80% and enhancers of 60% of E2-inducible genes displayed closed chromatin configuration both in the absence and presence of E2. Integration of ATAC-seq data with ERα ChIP-seq data revealed that ~40% ERα binding sites in the genome are found in chromatin regions that are not accessible as per ATAC-seq. Such ERα binding regions were enriched for binding sites of multiple nuclear receptors including ER, ESRRB, ERRγ, COUP-TFII (NR2F2), RARα, EAR2 as well as traditional pioneer factors FOXA1 and GATA3. Similar data were also obtained when ERα ChIP-seq data were integrated with MNase-seq and DNase-seq data sets. In summation, our results reveal complex mechanisms of ER-E2 interaction with nucleosomes. Notably, "closed chromatin" configuration as defined by ATAC-seq or by other techniques is not necessarily associated with lack of gene expression and technical limitations may preclude ATAC-seq to demonstrate accessibility of chromatin regions that are bound by ERα.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33420376     DOI: 10.1038/s41388-020-01607-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

2.  Meta-analysis of Chromatin Programming by Steroid Receptors.

Authors:  Ville Paakinaho; Erin E Swinstead; Diego M Presman; Lars Grøntved; Gordon L Hager
Journal:  Cell Rep       Date:  2019-09-24       Impact factor: 9.423

Review 3.  Genomic analyses of hormone signaling and gene regulation.

Authors:  Edwin Cheung; W Lee Kraus
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 4.  Endocrine-responsive breast cancer and strategies for combating resistance.

Authors:  Simak Ali; R Charles Coombes
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

Review 5.  Chromatin reprogramming in breast cancer.

Authors:  Erin E Swinstead; Ville Paakinaho; Gordon L Hager
Journal:  Endocr Relat Cancer       Date:  2018-04-24       Impact factor: 5.678

6.  ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands.

Authors:  Willem-Jan Welboren; Marc A van Driel; Eva M Janssen-Megens; Simon J van Heeringen; Fred Cgj Sweep; Paul N Span; Hendrik G Stunnenberg
Journal:  EMBO J       Date:  2009-04-04       Impact factor: 11.598

Review 7.  Pioneer transcription factors: establishing competence for gene expression.

Authors:  Kenneth S Zaret; Jason S Carroll
Journal:  Genes Dev       Date:  2011-11-01       Impact factor: 11.361

Review 8.  Pioneer factors in hormone-dependent cancers.

Authors:  Kamila M Jozwik; Jason S Carroll
Journal:  Nat Rev Cancer       Date:  2012-05-04       Impact factor: 60.716

9.  PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.

Authors:  Luca Magnani; Elizabeth B Ballantyne; Xiaoyang Zhang; Mathieu Lupien
Journal:  PLoS Genet       Date:  2011-11-17       Impact factor: 5.917

10.  Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.

Authors:  Guojuan Jiang; Xinrui Wang; Dandan Sheng; Lei Zhou; Yang Liu; Congling Xu; Suling Liu; Ji Zhang
Journal:  Theranostics       Date:  2019-08-21       Impact factor: 11.556

View more
  2 in total

Review 1.  Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer.

Authors:  Aditi S Khatpe; Adedeji K Adebayo; Christopher A Herodotou; Brijesh Kumar; Harikrishna Nakshatri
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

2.  The Estrogen Receptor α Signaling Pathway Controls Alternative Splicing in the Absence of Ligands in Breast Cancer Cells.

Authors:  Jamal Elhasnaoui; Giulio Ferrero; Valentina Miano; Santina Cutrupi; Michele De Bortoli
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.